Drug Target Review

JUNE 11, 2025

A known obstacle of biomedical data, with its inherent heterogeneity and inconsistencies, is that it presents significant challenges for creating a unified, high-quality knowledge base to fuel large language models (LLMs).

Drugs 64

Drugs Clinical Trials Drug Development Pharmaceuticals 64

The Pharma Data

JANUARY 10, 2021

Chief Executive Officer of MorphoSys, will present at the 39 th Annual J.P. EST. Live audio of the presentation can be accessed from the Media and Investors section under Conferences on MorphoSys’ website, www.morphosys.com. The presentation as well as a replay of the webcast will also be available on MorphoSys’ website.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Supply Trials 52

The Pharma Data

JUNE 15, 2025

The data, which encompass up to 3 years of follow-up after a single infusion of the treatment, were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held from June 13–16 in Glasgow, United Kingdom.

Treatment 40

Treatment Therapies Licensing Licensing 40

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Drug Hunter

JUNE 25, 2023

This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, and brain-penetrant HER2 and ROCK2 inhibitors.

Targeted Protein Degradation 130

Targeted Protein Degradation Computational Chemistry Trials Licensing 130

The Pharma Data

DECEMBER 13, 2020

The FDA also recommended that Gamida Cell generate additional manufacturing-related data prior to requesting a pre-Biologics License Application (BLA) meeting. During the meeting, the FDA provided encouraging feedback regarding the Phase 3 study of omidubicel pertaining to the pre-specified primary and secondary endpoints. About Omidubicel.

Licensing 52

Licensing Licensing Clinical Trials FDA 52

The Pharma Data

OCTOBER 26, 2020

(Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. AR-711 (COVID-19). AR-201 (RSV infection).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8

Licensing 40

Licensing Licensing Production Engineering 40

Drug Patent Watch

JANUARY 14, 2025

From mergers and acquisitions to licensing agreements and pricing discussions, these complex interactions demand a unique blend of scientific knowledge, business acumen, and interpersonal skills. These tools offer new opportunities for global collaboration but also present challenges in building rapport and reading non-verbal cues.

Pharmaceuticals 54

Pharmaceuticals Compliance Licensing Licensing 54

Twist Bioscience

APRIL 3, 2025

Learn More > Variant Libraries Order Now TCR Libraries New Combinatorial Variant Library Spread Out Low Diversity Libraries Site Saturation Libraries Enzyme Screening Kits New Watch how Twist builds variant libraries for your perfect application Synthetic Controls Order Now Liquid Biopsy cfDNA Pan-Cancer Reference Standards v2 New Infectious Disease (..)

RNA 52

RNA Virus Licensing Licensing 52

The Pharma Data

JUNE 14, 2023

Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Licensing 40

Licensing Licensing Small Molecule Science 40

The Pharma Data

NOVEMBER 10, 2020

The poster presentation, given by Johan Sandin , CSO at AlzeCure, presents how the mechanisms in the research platform Alzstatin work and shows that the target mechanism within the platform is suitable as a new treatment for Alzheimer’s disease. STOCKHOLM , Nov. About AlzeCure Pharma AB (publ).

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

Perficient: Drug Development

AUGUST 12, 2024

Additionally, AIS often incurs significantly lower licensing and maintenance costs, making it an attractive option for organizations looking to optimize their IT expenditure. Azure Integration Services offers a more cost-effective solution compared to MuleSoft, primarily due to its consumption-based pricing model.

Compliance 105

Compliance Licensing Licensing Production 105

The Pharma Data

JANUARY 27, 2021

Renowned lymphoma expert Mats Jerkeman, MD, Lund University, will give a presentation on the current treatment landscape, and unmet medical need for patients with relapsed or refractory NHL. .” BioInvent will hold a key opinion leader (KOL) call today, Thursday, January 28 at 5:30 p.m. CET ( 11:30 a.m.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

Perficient: Drug Development

JANUARY 19, 2024

This distribution utilizes licensed API keys, streamlining the process for customers to conveniently retrieve and access these containers in their local registries or incorporate them seamlessly into their CI/CD pipelines.

Compliance 118

Compliance Marketing Licensing Licensing 118

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

NOVEMBER 4, 2020

5, 2020 /PRNewswire/ — Bactiguard presents updated financial targets for 2025 in connection with the company’s financial report for the third quarter of 2020. We have several interesting licensing projects ongoing and see new, exciting business opportunities. The presentation can be followed at www.bactiguard.com.

Licensing 52

Licensing Licensing Production Marketing 52

Drug Hunter

APRIL 20, 2023

The development of a commercial manufacturing process involving deuterated building blocks is notable given the fact that the non-deuterated species has different pharmacology (lower selectivity due to an active metabolite), presenting a significant CMC challenge that needed to be overcome.

Small Molecule 130

Small Molecule Clinical Trials Trials Licensing 130

Fierce BioTech

DECEMBER 13, 2023

7 “Make or Break” Factors for Emerging Biopharma Companies This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Licensing 52

Licensing Licensing Science Production 52

The Pharma Data

DECEMBER 13, 2020

A webcast of the conference call will be available under “News and Presentations” in the Investors & Media section of Relay Therapeutics’ website at [link]. To access the live call, please dial 1 (833) 540-1168 (domestic) or 1 (929) 517-0359 (international) and refer to conference ID 8792127.

Licensing 40

Licensing Licensing Clinical Trials Small Molecule 40

Fierce BioTech

JULY 12, 2023

With so many sources of data, both in-house and licensed, we know it can be hard to sort through it all and analyze what you need to answer your research questions. Real-World Data for Cardiovascular Disease Research These days, top-tier biopharma companies are using real-world data (RWD) to power their cardiovascular disease research.

Disease 52

Disease Research Licensing Licensing 52

FDA Law Blog: Biosimilars

JANUARY 11, 2024

HPM) Directors, Karla Palmer and Dara Levy , will present at the Puerto Rico Pharmaceutical Summit 2024, February 6, 2024, at the La Concha Renaissance San Juan Resort in San Juan, Puerto Rico. Two Hyman, Phelps & McNamara, P.C.

Pharmaceuticals 59

Pharmaceuticals Licensing Licensing Compliance 59

Agency IQ

MARCH 25, 2024

In proposed rule, FDA offers up a (surprisingly sparse) list of drugs that present demonstrable compounding difficulties FDA yesterday released a long-awaited proposed rule on a list of drug products that present demonstrable difficulties for compounding.

FDA 40

FDA Pharmacy Drugs Production 40

Advarra

APRIL 30, 2024

A cross-check ensures curriculum vitae (CVs), and medical licenses (if appropriate) are on file and current. The FDA 1572 Form, CV, financial disclosure form, and medical license should all show consistency regarding the PI’s name. Both the medical licenses and nurse licenses need to be up to date.

Licensing 52

Licensing Licensing Pharmacy FDA 52

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

This product was developed by uniQure prior to being licensed to CSL Behring. However, there are many treatment goals that patients and their caregivers have that fall short of a cure, not only improvements but, for progressive conditions, a slowing or halting of worsening.

Therapies 119

Therapies FDA FDA Approval Treatment 119

Drug Target Review

APRIL 14, 2025

This model not only promises a broader market but also presents tangible benefits for patients. coli and yeast, but spirulina presents a new set of considerations. By definition, preventative drugs are taken by a larger number of customers because you never know exactly whos going to get an infection its probabilistic.

Therapies 52

Therapies Marketing Drug Development Treatment 52

The Pharma Data

APRIL 20, 2023

These data will be presented at the American Academy of Neurology (AAN) Annual Meeting held in Boston and virtually on April 22-27, 2023. A separate analysis showed that treatment with Kesimpta for up to five years was well-tolerated, with no new or increased safety risks identified 2.

Treatment 40

Treatment Trials Disease Licensing 40

Drug Target Review

FEBRUARY 1, 2024

Part of the challenge is that patients present with very different kinds of clinical phenotypes, meaning the populations are heterogeneous. This can present challenges when attempting to recruit an enriched patient population for clinical trials. We were able to license a molecule from a multi-national pharmaceutical company.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

BioPharma Drive: Drug Pricing

JUNE 23, 2025

Most Popular A longer ‘winter’: Public funding slowdown heightens pressure on biotech startups Gene therapy faces fresh uncertainty as two more top FDA officials depart FDA to speed reviews for drugs supporting ‘national interests’ A startup banks $66M to pursue ‘inclusive precision medicine’ Library resources Survey Report Pharma's AI and RWD (..)

Treatment 130

Treatment Drugs Therapies FDA 130

The Pharma Data

OCTOBER 15, 2020

Data was presented at the International Society of Pediatric Oncology (“SIOP”) Virtual Annual Congress held October 14 through October 17, 2020 in Ottawa, Canada. N axitamab In a poster presentation, Dr. Mora presented data from the Company’s pivotal 201 multicenter study. About Y-mAbs.

Licensing 52

Licensing Licensing Production Treatment 52

Policy Prescription

MAY 28, 2021

They have been getting it from Canada and are now wondering with this presentation, if that is dangerous.”. and licensed by your state board of pharmacy.” state-licensed board of pharmacy licensed pharmacy.”. state-licensed board of pharmacy licensed pharmacy.”. Emphasis added). over the past 20 years.

Pharmacy 52

Pharmacy Licensing Licensing Online Pharmacies 52

New Drug Approvals

JUNE 11, 2025

5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. 1] It is taken orally. [1] 1] Side effects of gepirone include dizziness , nausea , insomnia , abdominal pain , and dyspepsia (indigestion). [1] 1] Gepirone acts as a partial agonist of the serotonin 5-HT 1A receptor. [1]

FDA 62

FDA FDA Approval Treatment Clinical Trials 62

Perficient: Drug Development

MARCH 5, 2024

Assigning the Right License Access to objects is determined based on the license type, such as High-Volume Customer Community, Customer Community Plus, and Partner Community. MFA mandates users to present two or more authentication factors, such as a password and a security token, to gain access to the system.

Licensing 59

Licensing Licensing International Regulations 59

The Pharma Data

JUNE 6, 2025

The data, presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress in Vienna, Austria, mark a significant clinical advance, highlighting the potential of a novel mechanism of action that targets the underlying immunologic pathways driving IgAN progression.

Trials 40

Trials Treatment FDA Therapies 40

SugarCone Biotech

JUNE 10, 2024

4-1BB enhances the response of activated T-cells to “foreign antigens”: protein fragments derived from infected, diseased or cancerous cells that are presented to T cells by antigen-presenting cells (APC). The NIMBY problem I think the “Cancer Immunity Cycle” as originally presented by Chen and Mellman ( 10.1016/j.immuni.2013.07.012

Immune Response 87

Immune Response Production Regulations Clinical Trials 87

The Pharma Data

NOVEMBER 9, 2021

We delivered strong functional performance, with all divisions showing strong growth instigation,” said Werner Baumann, Chairman of the Board of Management, on Tuesday when presenting the company’s third- quarter results. percent), driven by earnings in North America due to lower product returns and the after damage of license earnings.

Licensing 52

Licensing Licensing Science Production 52

The Pharma Data

MARCH 8, 2021

These preliminary findings were presented today during Science Spotlights TM at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021). Findings from the primary efficacy and safety endpoints and additional secondary objectives will be presented at an upcoming medical meeting. About Ridgeback Biotherapeutics.

Trials 69

Trials Virus RNA Research Laboratories 69